

## Mini Budget

Less negative than expected; inflationary but should help contain twin deficits

- After a few delays, the government finally presented the Mini Budget in the Parliament, the approval of which will fulfill one of the two IMF pre-conditions for resumption of the EFF Program (the other condition being amendments in the SBP Act for greater central bank autonomy). The proposed measures in the Budget will remove tax exemptions and temper hitherto concessionary rates (such as sales tax of less than the standard 17%) on various items which include imported food, plant and machinery, agricultural inputs, medical supplies and automobiles.
- Broadly the measures will be inflationary as retail prices of many consumer items will rise by at least 5%. Since many imported goods are being targeted, ultimately the measures will help contain CAD and also increase tax collection by an estimated PKR350bn (c.0.7% of GDP). The government asserts that the measures will not hurt the poor, while it has not increased tax on key farmer inputs such as fertilizers and tractors. Hence the resultant increase in public discontent for the PTI government can be moderate, in our view.
- Sectors which will be negatively affected include Automobiles and some service industries (retail in particular). There are some positive surprises too, where some negative measures anticipated by the market did not come through. Particularly, the Dairy sector remains zero-rated and GST on locally manufactured tractors remains at 5% (not increased to 17%).
- We think the initial market response to the Mini Budget will be mildly positive as its approval makes the resumption of IMF Program more likely, without much loss of political capital for the government. Apart for the Auto OEMs, it is broadly neutral for other sectors. We highlight that the market is trading close to multiyear trough levels (forward P/E of c.4.8x).

Sector	Measure	Comments
Dairy	GST raised from 10% to 17% for dairy products other than UHT and pasteurized milk	UHT/pasteurized milk has remained Zero rated which should lead to strong rebound in FCEPL stock price (having corrected on fears of zero rating reversal) - UHT segment accounts for c. 80% of its revenues. Powdered milk for tea whitener has been proposed to be moved from zero rating to 17% GST regime which will affect NESTLE, FCEPL, FFL – the impact of which is likely to be passed on to consumers.
	GST raised on raw material for preparation of infant products	GST on other fat filled milk products (fortified milk, infant milk, yoghurt, cheese, butter, ghee) will increase from 10% to 17%, negatively affecting FCEPL, NESTLE, FFL, PREMA, and SML. However, we expect most of these names to pass on the impact. 17% GST on imported infant milk formula will prove to benefit local players such as ICI (Morinaga-Nutrico), ABOT, SEARL, IBLHL. On the flip side, GST on raw material used in infant formula at import stage will be negative. GST on import of live animals and bovine semen will negatively impact PREMA due to its substantial import volume; FCEPL, NESTLE, and FFL will be less negatively affected.
Tractor	Retention of GST at 5%	GST on tractors is maintained at 5%. This is likely to spark a rally in the sector which has underperformed recently on expectations of a hike in GST. The present demand growth momentum (up c.20% yoy in 5MFY22) is likely to sustain amid robust farmer income, in our view. We look to revisit our estimates on passage of the Bill.
Autos	FED on all cars above 1,000cc have risen by 2.5-5% Cars between 850-1,000cc are now subject to 17% GST Imported EV CBUs are now subject to 17% GST (from 5%) GST on HEVs up to 1,800cc increased to 12.5%	The measures are negative for the OEMs and contradict the recently approved Auto Policy. The increase in GST on cars between 850-1,000cc will be negative for both PSMC and LUCK (Lucky Motor Corporation), while increases in FED will lead to further price hikes and slowdown in overall demand, in our view (impact on all cars above 850cc). While an increase in FED on imported CBUs is positive for the sector, higher FED on locally manufactured double cabin pickups is negative for both INDU and GHNI.
Textile	Imposition of GST on local supplies of raw cotton	The Budget is broadly Neutral for the sector, as the cash-flow impact of higher taxes on inputs will be countered by improved refunds in the system. This, however, may encourage the industry to increase the procurement of imported cotton, in our view.
Fertilizer	GST of 2% is unchanged	The GST on all fertilizer products including Urea, DAP and others remain unchanged at 2%. An increase would have been neutral for the producers as they would have passed on the increase in prices, but it would have been negative for the farmers.

Sector	Measure	Comments
<b>Pharma</b>	<p>Increase in GST on APIs from 0% to 17% while moving from Exempt to Zero-rated status on local supplies</p> <p>Widespread rise in GST for pharmaceutical equipment and hospital supplies/imported equipment</p>	<p>Pharma companies were Exempt from GST i.e. they neither paid sales tax (0% rate) nor claimed input tax. It is proposed to raise GST to 17% on API import stage. However, Pharma companies are also moved from Exempt to Zero rated status on local supplies (following sale of final product), allowing input tax to be claimed not only on APIs but packaging and materials as well. This would result in a net positive impact for pharma companies.</p> <p>Import of equipment for TB, AIDS and Cancer are no longer GST exempt; this would be negative for SHFA.</p>
<b>IT &amp; Telecom</b>	<p>17% GST on mobile phones and import of machinery</p> <p>Increase in taxes on phone calls, recharge and internet usage</p>	<p>Import of machinery for mobile-phone assembling and mobile phones (CBU) having value of US\$200 and above to be imposed with 17% GST.</p> <p>Sale price of internet card, telephone card or phone call will increase as income tax will be raised to 15% from 8-10%. Consumption of telecom services will moderate.</p>
<b>Miscellaneous</b>	<p>Widespread increase in GST for sugar, poultry feed, seeds, lithium ion batteries, imported vegetables and several essential goods</p>	<p>Sugar supplied as an industrial raw material to pharmaceutical, beverage and confectionery industries will now be subject to GST</p> <p>Import of red chilies are no longer GST exempt which would prove beneficial for local players (NATF)</p> <p>Import of sunflower and canola seeds are no longer GST exempt – negative for ICI and UNITY</p> <p>GST raised on lithium ion phosphate batteries from 12% to 17% - negative for EXIDE, ATBA</p> <p>GST raised to 17% on prepared foods, sweet meats, bakeries, caterers, restaurants will prove inflationary</p> <p>17% GST proposed to be imposed on several imported essential items including vegetables, poultry, eggs, contraceptives etc.</p>

Source: IMS Research

We, IMS Research Team, certify that the views expressed in the report reflect our personal views about the subject securities. We also certify that no part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations made in this report. We further certify that we do not have any beneficial holding of the specific securities that we have recommendations on in this report.

Ratings Guide*	Criteria
Buy	Total return expectation of $\geq 15\%$ or expected to outperform the KSE-100 index
Neutral	Total return expectation of $> -5\%$ or expected to match the return of KSE-100 index
Sell	Expected downside of more than 5% or expected to underperform the KSE-100 index

\*Based on 12 month horizon unless stated otherwise in the report.

**Valuation Methodology:** We use multiple valuation methodologies in arriving at a Target Price including, but not limited to, Discounted Cash Flow (DCF), Dividend Discount Model (DDM) and relative multiples based valuations.

**Risks:**(i) These measures will be inflationary, (ii) public discontent rises ahead of elections in 2023 (iii) lower GDP growth.

**Disclaimer:** Intermarket Securities Limited has produced this report for private circulation only. The information, opinions, and estimates herein are not direct at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject Intermarket Securities Limited to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable where such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness, and correctness. This report makes use of forward looking statements that are based on assumptions made and information currently available to us and those are subject to certain risks and uncertainties that could cause the actual results to differ materially. No part of the compensation of the author(s) of this report is related to the specific recommendations or views contained in this report.

This report is not a solicitation or any offer to buy or sell any of the securities mentioned herein. It is meant for information purposes only and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this report, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice. Neither Intermarket Securities Limited nor any of its affiliates or any other person associated with the company directly or indirectly accepts any liability whatsoever for any direct or consequential loss arising from any use of this report or the information contained herein.

Subject to any applicable law and regulations, Intermarket Securities Limited, its affiliates or group companies or individuals connected with Intermarket Securities Limited directly or indirectly may have used the information contained herein before publication and may have positions in, or may from time to time purchase or sell or have a material interest in any of the securities mentioned or may currently or in future have or have had a relationship with, or may provide investment banking, capital markets and/or other services to, the entities mentioned herein, their advisors and/or any other connected parties.

## RESEARCH DISCLOSURES

### Third Party Research

This is third party research. It was prepared by Intermarket Securities Limited (IMS), with headquarters in Karachi, Pakistan. Intermarket Securities Limited (IMS) is authorized to engage in securities activities according to its domestic legislation. Intermarket Securities Limited (IMS) has sole control over the contents of this research report.

Intermarket Securities Limited (IMS) is the employer of the research analyst(s) responsible for the content of this report and research analysts preparing this report are resident outside the U.S. and are not associated persons of any U.S. regulated broker-dealer. The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

None of the materials provided in this report may be used, reproduced, or transmitted, in any form or by any means, electronic or mechanical, including recording or the use of any information storage and retrieval system, without written permission.

### Disclaimers

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Frontier and Emerging Market laws and regulations governing investments in securities markets may not be sufficiently developed or may be subject to inconsistent or arbitrary interpretation or application. Frontier and Emerging Market securities are often not issued in physical form and registration of ownership may not be subject to a centralized system. Registration of ownership of certain types of securities may not be subject to standardized procedures and may even be effected on an ad hoc basis. The value of investments in Frontier and Emerging Market securities may also be affected by fluctuations in available currency rates and exchange control regulations. Not all of these or other risks associated with the relevant company, market or instrument which are the subject matter of the report are necessarily considered.

### US Distribution

This Report is considered independent third-party research and was prepared by **Intermarket Securities Limited (FBD)**, with headquarters in **Pakistan**. The distribution of this Research is provided pursuant to the exemption under Rule 15a-6(a)(2) and is only intended for an audience of Major U.S. Institutional Investors (MUSIs) as defined by Rule 15a-6(b)(4). This research is not a product of **StoneX Financial Inc.** **Intermarket Securities Limited** has sole control over the contents of this research report. **StoneX Financial Inc.** does not exercise any control over the contents of, or the views expressed in, any research reports prepared by **Intermarket Securities Limited** and under Rule 15a-6(a)(3), any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through **StoneX Financial Inc.** For any information, please contact Gene Turok. Under no circumstances should any U.S. recipient of this research report effect any transaction to buy or sell securities or related financial instruments through **Intermarket Securities Limited**.

**Intermarket Securities Limited (IMS)** is not registered as a broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" and other "U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

### Distribution outside US

This report is not intended for distribution to the public and may not be reproduced, redistributed or published, in whole or in part, for any purpose without the written permission of Tellimer. Tellimer shall accept no liability whatsoever for the actions of third parties in this respect. This report is for distribution only under such circumstances as may be permitted by applicable law.

This report may not be used to create any financial instruments or products or any indices. Neither Tellimer, nor its members, directors, representatives, or employees accept any liability for any direct or consequential loss or damage arising out of the use of all or any part of the information herein.

**United Kingdom:** Distributed by Exotix Partners LLP only to Eligible Counterparties or Professional Clients (as defined in the FCA Handbook). The information herein does not apply to, and should not be relied upon by, Retail Clients (as defined in the FCA Handbook); neither the FCA's protection rules nor compensation scheme may be applied.

**UAE:** Distributed in the Dubai International Financial Centre by Exotix Partners LLP (Dubai) which is regulated by the Dubai Financial Services Authority ("DFSA"). Material is intended only for persons who meet the criteria for Professional Clients under the Rules of the DFSA and no other person should act upon it.

**Other distribution:** The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restriction